Beyond PD-L1: Taking away TIM3 and Tregs stops cancer regrowth after immunotherapyApril 16, 2018
Radiation treatment can boost the effectiveness of anti-cancer immunotherapy. Still, some patients fail to respond to this combination, and while the combination of radiotherapy and immunotherapy is very good at creating remission, it's not very good at sustaining it. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 shows how tumors may learn to overcome this combination treatment: Increased TIM3 and/or increased regulatory T cells (Tregs) within the tumor may help cancers inactivate immune system killer T cells that would otherwise identify and attack the cancer. The findings may help design combination therapies that reduce relapse after immunotherapy.
"Sometimes you give radiation alone and it doesn't work, or you give immunotherapy alone and it doesn't work," says Sana Karam, MD, PhD, investigator at the CU Cancer Center and assistant professor in the CU School of Medicine Department of Radiation Oncology. "But combine the two and--boom!--you get this huge synergy. Unfortunately, the effect is often transient, and we wanted to know why."
To answer this question, Karam and colleagues including first author Ayman Oweida, PhD, analyzed tumor RNA during "response" and "resistance" phases, allowing them to look for differences in gene activation when radiotherapy/immunotherapy was working and when it eventually stopped working. There was, in fact, a stark difference: In tumors that had become resistant to combination radiotherapy/immunotherapy, the gene TIM3 was dramatically more active.
This makes sense - tumors likely use TIM3 to hide themselves from the immune system.
Here's how it works: Immune system T cells search for and attack foreign cells. But during a pregnancy, for example, there are foreign-like cells that we would rather these T cells not attack. For this reason, T cells come equipped with an "off" switch. T cells coat themselves in a protein called PD-1. And some cells present a partner called PD-L1. When the PD-1 on T cells detects PD-L1 on another cell, the T cells are turned off and do not attack. Many cancer cells express PD-L1 as a way to cloak themselves from the immune system and a successful strategy of anti-cancer immunotherapy has been the use of PD-L1 inhibitors such as pembrolizumab and nivolumab to stop the ability of cancer cells to express PD-L1 and thus hide from immune system T cells.
The interaction between T cells' PD-1 and tumor cells' PD-L1 is called a "checkpoint." TIM3 is an essential link in another checkpoint. The current study implies that when immunotherapy inhibits PD-1/PD-L1 checkpoint, cancers may learn to use the TIM3 checkpoint instead to hide from the immune system.
When Karam and colleagues added an experimental TIM3 inhibitor to radiotherapy/immunotherapy they were able to increase the duration of response in models of head and neck cancer.
"We got a much better response," Karam says. "You go from 30 days to 60 days, but if you watch long enough, you still end up with regrowth. The tumors still return."
The question remained: How were tumor cells evolving to resist therapy, this time in response to anti-PD-L1, anti-TIM3 and radiotherapy? The study shows that the answer may have to do with another of the body's important "off" switches.
"If you have a cold or infection, T cells come in to destroy the bacteria," Karam says. "But if T cells are constantly on, they result in autoimmune disease. Nature is so smart that you have a population of cells that can turn off these T cells. We call these regulatory T cells, or Tregs."
When the group again explored differences between tumors that responded to this three-part therapy and tumors that were resistant, they found that resistant tumors were shot-through with Tregs. In other words, the tumors had again discovered a way to inactivate immune system T cells, this time by the use of Tregs.
But when the group went a step further, testing TIM3 inhibition with PD-L1 inhibition with radiotherapy in the absence of Tregs, "We eradicated the tumor completely," Karam says. Not only did this combination therapy eradicate the existing tumor, but when Karam reintroduced cancer cells to the model, these cells failed to grow new tumors.
TIM3 inhibition has already been hypothesized as an immunotherapy alone or in combination with PD-L1 inhibition, and experimental TIM3 inhibitors already exist. However, no strong strategy exists to rid tumors of Tregs. The group's ongoing work hopes to pick apart the strategies that Tregs use to inactivate T cells.
Intricacies of the science remain. But discovering and inhibiting the mechanisms that tumor cells use to inactivate the immune system, Karam says, "could be a game-changer for clinical practice in the way we manage many cancers."
University of Colorado Anschutz Medical Campus
Related Cancer Articles:
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Is investment in research to develop new treatments the best approach to controlling cancer?
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.
Related Cancer Reading:
The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)
Winner of the Pulitzer Prize, and now a documentary from Ken Burns on PBS, The Emperor of All Maladies is a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence.
Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly... View Details
AJCC Cancer Staging Manual
by Mahul B. Amin (Editor), Stephen B. Edge (Editor), Frederick L. Greene (Editor), David R. Byrd (Editor), Robert K. Brookland (Editor), Mary Kay Washington (Editor), Jeffrey E. Gershenwald (Editor), Carolyn C. Compton (Editor), Kenneth R. Hess (Editor), Daniel C. Sullivan (Editor), J. Milburn Jessup (Editor), James D. Brierley (Editor), Lauri E. Gaspar (Editor), Richard L. Schilsky (Editor), Charles M. Balch (Editor), David P. Winchester (Editor), Elliot A. Asare (Editor), Martin Madera (Editor), Donna M. Gress (Editor), Laura R. Meyer (Editor)
The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neoplastic diseases. Proper classification and staging of cancer is essential for the physician to assign proper treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.
Significantly expanded and developed by international disease site expert panels, the Eighth Edition AJCC Cancer Staging Manual brings together all... View Details
F*ck Cancer: A totally inappropriate self-affirming adult coloring book (Totally Inappropriate Series) (Volume 4)
by Jen Meyers (Author)
*A portion of the proceeds from this book will be donated to support research dedicated to finding a cure for cancer. Because fuck cancer.
This book is for you.
If you are fighting cancer, this is for you. If your brother, sister, mom, dad, son, daughter, relative, or friend is fighting cancer, this is for you. If you've lost someone to cancer like I have, this is for you. If cancer affects your life in any way, this is for you.
The stress of cancer can feel crushing. But perhaps this book can help you get away from it all, if only for a little... View Details
The Truth about Cancer: What You Need to Know about Cancer's History, Treatment, and Prevention
by Ty M Bollinger (Author)
Cancer touches more lives than you may think. According to the World Health Organization, one out of three women alive today, and one out of two men, will face a cancer diagnosis in their lifetime.
To Ty Bollinger, this isn’t just a statistic. It’s personal. After losing seven members of his family to cancer over the course of a decade, Ty set out on a global quest to learn as much as he possibly could about cancer treatments and the medical industry that surrounds the disease. He has written this book to share what he’s uncovered—some of which may shock you—and to give you... View Details
The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery
by Rebecca Katz (Author), Mat Edelson (Author)
This new and revised edition of the IACP award-winning cookbook brings the healing power of delicious, nutritious foods to those whose hearts and bodies crave a revitalizing meal, through 150 new and updated recipes.
Featuring science-based, nutrient-rich recipes that are easy to prepare and designed to give patients a much-needed boost by stimulating appetite and addressing treatment side effects including fatigue, nausea, dehydration, mouth and throat soreness, tastebud changes, and weight loss. A step-by-step guide helps patients nutritionally prepare for all phases of... View Details
The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-Individualized Therapies
by Dr. Nasha Winters ND FABNO L.Ac Dipl.OM (Author), Jess Higgins Kelley MNT (Author), Kelly Turner (Foreword)
The Optimal Terrain Ten Protocol to Reboot Cellular Health
Since the beginning of the twentieth century, cancer rates have increased exponentially―now affecting almost 50 percent of the American population. Conventional treatment continues to rely on chemotherapy, surgery, and radiation to attack cancer cells. Yet research has repeatedly shown that 95 percent of cancer cases are directly linked to diet and lifestyle. The Metabolic Approach to Cancer is the book we have been waiting for―it offers an innovative, metabolic-focused nutrition protocol that... View Details
Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)
The revolutionary, New York Times bestselling guide to the powerful lifestyle changes that fight and prevent cancer—an integrative approach based on the latest scientific research
“A common-sense blueprint for healthy living.” —Chicago Tribune
“Resonating with cancer support communities and recommended nationwide.” —Los Angeles Times
“Life affirming . . . filled with practical advice.” —The Seattle Times
David Servan-Schreiber was a rising... View Details
Cancer: 50 Essential Things to Do: 2013 Edition
by Greg Anderson (Author)
The ground-breaking classic guide to surviving cancer?now completely updated!
Revised and updated for the first time since 1999, this invaluable guide to cancer recovery offers an easily accessible plan for patients and family members. Written by a cancer survivor, the book is an inspiring, action-oriented roadmap for those who choose to adopt a stance of hope and take charge of their diagnosis.
With penetrating insights that bring together more than two decades of scientifically supported research and experience, Anderson reveals a step-by-step holistic action plan... View Details
50 Days of Hope: Daily Inspiration for Your Journey through Cancer
by Lynn Eib (Author)
You’ve just heard a diagnosis that shakes your world: It's cancer. And what you long for most is the hope that everything will be okay. You are not alone. As a longtime cancer survivor, Lynn Eib knows firsthand how that feels. And as a patient advocate helping thousands facing cancer, she also knows what gives people hope. In 50 Days of Hope, Lynn shares amazing, true stories of those who have been in your shoes and discovered that when God and cancer meet, hope is never far away. Whether you’re a cancer patient or walking with a loved one on a cancer journey, you’ll find 50... View Details
Cancer: Step Outside the Box
by Ty M. Bollinger (Author)
Now in its 6th Edition (recently updated in 2014) and with over 150,000 copies sold since 2006, Cancer-Step Outside the Box is a “must-have” book that everyone should own. According to Dr. Rashid Buttar, author of The 9 Steps to Keep the Doctor Away, “Ty Bollinger's book, Cancer-Step Outside the Box, is an extraordinarily thorough and courageously well written book, brought to fruition by the dedication of a son for his departed parents. I found it difficult to put down this exceptional book once I began reading it and plan on recommending it to all my patients suffering from cancer who... View Details